Prelude Therapeutics Inc. (PRLD): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRLD Stock Price Chart Interactive Chart >
PRLD Price/Volume Stats
| Current price | $31.20 | 52-week high | $95.38 |
| Prev. close | $32.04 | 52-week low | $23.69 |
| Day low | $30.63 | Volume | 131,100 |
| Day high | $32.48 | Avg. volume | 219,472 |
| 50-day MA | $36.53 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 1.47B |
Prelude Therapeutics Inc. (PRLD) Company Bio
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
Latest PRLD News From Around the Web
Below are the latest news stories about Prelude Therapeutics Inc that investors may wish to consider to help them evaluate PRLD as an investment opportunity.
Prelude Therapeutics (PRLD) Enters Oversold TerritoryPrelude Therapeutics (PRLD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. |
Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor ConferencesWILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences: Barclays Global Healthcare ConferenceFireside chat at 8:35 a.m. ET on Wednesday, March 10, 2021 Morgan Stanley Virtual Healthcare Corporate Access Day1x1 meetings on Tuesday, March 16, 2021 Oppenheimer 31st Annual Healthcare ConferenceCorporate presentation at 3:50 p.m. ET on Wednesday, March 17, 2021 A live webcast of the Barclays fireside chat and Oppenheimer presentation can be accessed under “Events & Presentations” in the Investor Section of the Company’s website, https://investors.preludet... |
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesWILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share, which includes the exercise in full of the underwriters’ option to purchase an additional 375,000 shares of its voting common stock. The aggregate gross proceeds from this offering were $172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude. Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities and Barclays acted as joint book-running ma... |
Prelude Therapeutics Announces Pricing of Upsized Public OfferingWILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its upsized public offering of 2,208,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share. The aggregate gross proceeds from this offering are expected to be $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude. In addition, Prelude has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of voting common stock at the public offering price, less underwriting d... |
Prelude Therapeutics Announces Launch of Proposed Public OfferingWILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (“SEC”). All shares of common stock to be sold in the offering will be sold by Prelude. In addition, Prelude expects to grant the underwriters a 30-day option to purchase up to an additional 262,500 shares of common stock at the public offering price, less underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.... |
PRLD Price Returns
| 1-mo | -25.78% |
| 3-mo | -46.03% |
| 6-mo | -55.38% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -56.39% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...